Physician profile
Jordan E Genut
NPI 1285861005
$3,113.69
in general payments reported to CMS, 2019-2025
11 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $65.10 · 2022: $77.53 · 2023: $31.39 · 2024: $1,151 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,138 · Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,137.76 |
| Food and Beverage | $629.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $2,813.93 | 2019-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis |
| Medtronic, INC. | $86.65 | 2022-2025 | Venaseal |
| Silk Road Medical, INC. | $48.56 | 2020-2022 | |
| Cook Medical LLC | $26.98 | 2025 | Rosen |
| Terumo Medical Corporation | $23.68 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.96 | 2024 | Lifevest |
| Boston Scientific Corporation | $19.98 | 2024 | Varithena Administration Pack |
| Bard Peripheral Vascular, INC. | $19.29 | 2022 | |
| Solventum Corporation | $18.12 | 2025 | Activ.A.C., Promogran Prisma |
| Smith+Nephew, INC. | $17.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.15 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Genut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.